Scancell - SCIB1 patent granted

Tuesday, Oct 25 2011 by

Scancell, the Nottingham based cancer vaccine developer, announced that a European composition of matter patent has been granted for SCIB1, the company's lead vaccine. SCIB1 is being developed for the treatment of melanoma and is currently in phase I clinical trials.

The SCLP share price has decreased by 41% over the last year.

Scancell Holdings Plc is currently graded c by LCF Research. To learn more, follow the link.


Disclaimer:  

This note was prepared by LCF Research Limited using information provided by the subject company’s management or publically available news sources. No representations are made nor warranties given (express or implied) in relation to accuracy and completeness. This document is not an invitation to invest in the subject company and does not purport to contain all the necessary information that a prospective investor might require. LCF Research Limited recommends prospective investors to conduct their own thorough independent analysis of the subject company and the information contained in this note or referred to above.


Do you like this Post?
Yes
No
0 thumbs up
0 thumbs down
Share this post with friends



Scancell Holdings plc is a biopharmaceutical company focused on the cancer therapeutics market. The Company's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The Company is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The Company's products include SCIB1, SCIB2 and Modi-1. The Company's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. It is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The Company's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide. more »

LSE Price
14.88p
Change
 
Mkt Cap (£m)
38.9
P/E (fwd)
n/a
Yield (fwd)
n/a



  Is Scancell Holdings fundamentally strong or weak? Find out More »


What's your view on this thread? Log In to Comment Now

You can track all @StockoChat comments via Twitter




Stock Picking Tutorial Centre


Related Content


Exciting science
Exciting science
Scancell Holdings 17th Jul '13

Building companies Whats going on
Building companies. What's going on?
Barratt Developments 2nd Aug



Let’s get you setup so you get the most out of our service
Done, Let's add some stocks
Brilliant - You've created a folio! Now let's add some stocks to it.

  • Apple (AAPL)

  • Shell (RDSA)

  • Twitter (TWTR)

  • Volkswagon AG (VOK)

  • McDonalds (MCD)

  • Vodafone (VOD)

  • Barratt Homes (BDEV)

  • Microsoft (MSFT)

  • Tesco (TSCO)
Save and show me my analysis
Foliobuilder